MaSTherCell And Curecell Sign Memorandum Of Understanding For Cell Therapy Partnership
Gosselies, Belgium – May 22, 2015 – MaSTherCell SA, a Contract Development and Manufacturing Organization (CDMO) specialized in the industrialization of cell therapy products, signed today a Memorandum of Understanding (MOU) with Korean company CureCell Co., Ltd. Under the agreement, both companies will form a joint venture primarily focusing on the development, manufacturing and commercialization of cell therapy products in Korea.
With this strategic collaboration, MaSTherCell expands its global presence and gains access to a state-of-the-art facility and a broad cell therapy network in Korea. “We are happy to have CureCell as a partner to support our international expansion strategy. CureCell is the best fit to help us in our ambition to penetrate the highly attractive and fast-growing Korean market and to become the ultimate gateway for cell therapy companies willing to address the Asian market,” said Hugues Bultot, CEO of MaSTherCell.
The newly formed alliance, facilitated by the Global Stem Cell & Regenerative Medicine Acceleration Center (GSRAC) provides a framework of collaborative research in cell therapy that aims to contribute to the regenerative medicine and industry growth in Korea. “The partnership reflects our vision for regenerative medicine, where MaSTherCell know-how and expertise in assay and process development as well as GMP manufacturing will help us to fast track our growth and leadership within the Korean cell therapy market,” added David Kim, CEO of CureCell.
The MOU is intended to be finalized by a definitive agreement and will be in effect until MaSTherCell signs a formal agreement with CureCell.
About CureCell
CureCell is a Korean based company focused on developing innovative regenerative therapies for both Korean and international markets. CureCell’s management has identified several cell-therapy technologies that are developed in Korea in parallel to potential developments in the US and Europe. CureCell will focus on developing foreign technologies in Korea and Asia and on expanding international markets for Korean technologies. CureCell collaborates closely with leading medical and academic facilities aiming to become a market leader in therapeutic development in Korea.
About MaSTherCell
MaSTherCell SA (Manufacturing Synergies for Therapeutic Cells), a spin-off from ULB (Université Libre de Bruxelles) launched in 2011, is a CDMO specialized in cell therapy development for advanced medicinal products. The company is located in Gosselies, Belgium and provides GMP manufacturing for cell therapy companies. Its mission is to combine expertise, quality systems and infrastructure to help its customers bring highly potent cell therapy products faster to the market. MaSTherCell believes that the best way to serve customers is to combine scientific and business expertise as well as operational acumen to provide an unequalled manufacturing service in the cell therapy field. Its technology-driven, quality-minded and customer-oriented team of committed experts is dedicated to achieving that mission. For more information, visit www.masthercell.com.
Help employers find you! Check out all the jobs and post your resume.
With this strategic collaboration, MaSTherCell expands its global presence and gains access to a state-of-the-art facility and a broad cell therapy network in Korea. “We are happy to have CureCell as a partner to support our international expansion strategy. CureCell is the best fit to help us in our ambition to penetrate the highly attractive and fast-growing Korean market and to become the ultimate gateway for cell therapy companies willing to address the Asian market,” said Hugues Bultot, CEO of MaSTherCell.
The newly formed alliance, facilitated by the Global Stem Cell & Regenerative Medicine Acceleration Center (GSRAC) provides a framework of collaborative research in cell therapy that aims to contribute to the regenerative medicine and industry growth in Korea. “The partnership reflects our vision for regenerative medicine, where MaSTherCell know-how and expertise in assay and process development as well as GMP manufacturing will help us to fast track our growth and leadership within the Korean cell therapy market,” added David Kim, CEO of CureCell.
The MOU is intended to be finalized by a definitive agreement and will be in effect until MaSTherCell signs a formal agreement with CureCell.
About CureCell
CureCell is a Korean based company focused on developing innovative regenerative therapies for both Korean and international markets. CureCell’s management has identified several cell-therapy technologies that are developed in Korea in parallel to potential developments in the US and Europe. CureCell will focus on developing foreign technologies in Korea and Asia and on expanding international markets for Korean technologies. CureCell collaborates closely with leading medical and academic facilities aiming to become a market leader in therapeutic development in Korea.
About MaSTherCell
MaSTherCell SA (Manufacturing Synergies for Therapeutic Cells), a spin-off from ULB (Université Libre de Bruxelles) launched in 2011, is a CDMO specialized in cell therapy development for advanced medicinal products. The company is located in Gosselies, Belgium and provides GMP manufacturing for cell therapy companies. Its mission is to combine expertise, quality systems and infrastructure to help its customers bring highly potent cell therapy products faster to the market. MaSTherCell believes that the best way to serve customers is to combine scientific and business expertise as well as operational acumen to provide an unequalled manufacturing service in the cell therapy field. Its technology-driven, quality-minded and customer-oriented team of committed experts is dedicated to achieving that mission. For more information, visit www.masthercell.com.
Help employers find you! Check out all the jobs and post your resume.